CJC-1295 vs Ipamorelin

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicCJC-1295Ipamorelin
What it is

A synthetic analogue of growth hormone-releasing hormone, 29 amino acids long. A version with an added drug affinity complex (DAC) binds to albumin in the blood and lasts longer.2

A synthetic peptide of five amino acids, including unnatural ones, that acts as a ghrelin mimetic and stimulates growth hormone release.3

FDA status

Not FDA-approved

Unapproved new drug in cited enforcement record1

Not FDA-approved. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among compounding substances that may present significant safety risks.2,4

Is CJC-1295 FDA-approved?

Not FDA-approved

Unapproved new drug in cited enforcement record1

Not FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.3,4

Is ipamorelin FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. CJC-1295 is not among them.5,6

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not among them.5,6

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists CJC-1295 among substances whose nominations were withdrawn, citing possible immune reactions, impurities and serious adverse events including increased heart rate.4

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, and among substances whose nominations were withdrawn. It cites possible immune reactions and a published report of serious adverse events, including death.4

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial Two placebo-controlled studies in healthy adults published in 2006, in which most participants received one or a few exposures to a CJC-1295 DAC substance and growth hormone and IGF-1 levels were measured.2
  • Small, short, or incompletely reported human study FDA counted 63 healthy adults, 87% of them men, exposed to a CJC-1295 DAC substance across three published studies; 73% received a single exposure.2
  • Animal or laboratory research Animal studies in which a CJC-1295 DAC substance acted as a growth hormone secretagogue, and toxicology studies in rats and dogs that showed bleeding, inflammation and tissue death where it was given.2

Smaller controlled human trials

  • Controlled human trial A Phase 2, multicenter, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults after bowel resection, of whom 114 received study drug, published in 2014. FDA reports that its main result was not statistically significant.3
  • Controlled human trial A randomized, placebo-controlled pharmacology study in 48 healthy men that measured blood levels and growth hormone responses. FDA notes it reported no effectiveness data.3
Records collected

0 ClinicalTrials.gov records and 9 PubMed records collected

2 ClinicalTrials.gov records and 14 PubMed records collected

Area of study

Hormones2

Hormones, Gut and digestion3

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, lists CJC-1295 among withdrawn nominations with safety concerns.4
  2. FDA’s Pharmacy Compounding Advisory Committee meets to discuss CJC-1295-related substances.2,7
  3. FDA staff date their evaluation recommending against adding CJC-1295-related substances to the 503A bulks list.2
  1. FDA’s compounding safety-risk page, as last updated, lists ipamorelin acetate in category 2 under the 503B interim policy and among withdrawn nominations.4
  2. FDA’s Pharmacy Compounding Advisory Committee meets to discuss ipamorelin-related substances.3,8
  3. A Federal Register notice announces the October 29, 2024 advisory-committee meeting that will discuss ipamorelin.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  2. 2
    FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  3. 3
    FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Federal Register notice 2024-24828 · published 2024-10-25 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  8. 8
    Federal Register notice 2024-21241 · published 2024-09-18 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026